Fintech PR
Essity reports Vinda as discontinued operations as of Q4 2023 and publishes updated comparable figures
![essity-reports-vinda-as-discontinued-operations-as-of-q4-2023-and-publishes-updated-comparable-figures](https://thefintechbuzz.com/wp-content/uploads/2023/12/48631-essity-reports-vinda-as-discontinued-operations-as-of-q4-2023-and-publishes-updated-comparable-figures.png)
STOCKHOLM, Dec. 19, 2023 /PRNewswire/ — As announced on December 15, 2023, Essity will, as of the fourth quarter of 2023, classify the financial reporting of Vinda as discontinued operations. Today, Essity is publishing updated comparable figures to reflect this change in accounting.
EARNINGS TREND
SEKm |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Net sales |
37,092 |
37,078 |
36,352 |
36,629 |
131,320 |
101,466 |
Gross profit |
10,683 |
10,454 |
10,359 |
9,935 |
32,026 |
29,144 |
Adjusted gross profit1 |
11,670 |
10,809 |
10,321 |
10,237 |
33,925 |
29,290 |
Adjusted operating profit before amortization of acquisition- related intangible assets (EBITA)1 |
5,147 |
4,617 |
4,281 |
4,112 |
12,047 |
11,451 |
Operating profit before amortization of acquisition-related intangible assets (EBITA) |
3,497 |
4,131 |
4,368 |
3,818 |
9,876 |
11,822 |
Amortization of acquisition-related intangible assets |
-277 |
-279 |
-283 |
-288 |
-1,111 |
-844 |
Adjusted operating profit1 |
4,870 |
4,338 |
3,998 |
3,824 |
10,936 |
10,607 |
Items affecting comparability |
-1,967 |
-519 |
87 |
-305 |
-2,445 |
371 |
Operating profit |
2,903 |
3,819 |
4,085 |
3,519 |
8,491 |
10,978 |
Financial items |
-644 |
-588 |
-625 |
-561 |
-1,320 |
-567 |
Profit before tax |
2,259 |
3,231 |
3,460 |
2,958 |
7,171 |
10,411 |
Adjusted profit before tax1 |
4,226 |
3,750 |
3,373 |
3,263 |
9,616 |
10,040 |
Income taxes |
-696 |
-786 |
-809 |
-736 |
-2,006 |
-2,398 |
Profit for the period from continuing operations |
1,563 |
2,445 |
2,651 |
2,222 |
5,165 |
8,013 |
Profit for the period from discontinued operations |
88 |
106 |
52 |
24 |
899 |
1,797 |
Profit for the period, total operations |
1,651 |
2,551 |
2,703 |
2,246 |
6,064 |
9,810 |
Earnings per share before and after dilution, continuing operation, SEK |
2.20 |
3.46 |
3.75 |
3.14 |
7.28 |
10.96 |
Adjusted earnings per share before and after dilution, continuing operation, SEK2 |
4.83 |
4.26 |
3.93 |
3.75 |
11.60 |
11.18 |
Earnings per share before and after dilution, total operations, SEK |
2.26 |
3.53 |
3.79 |
3.15 |
7.93 |
12.27 |
1Excluding items affecting comparability. |
||||||
2Excluding items affecting comparability and amortization of acquisition-related intangible assets. |
NET SALES BY BUSINESS AREA
SEKm |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
7,158 |
6,905 |
6,665 |
6,589 |
24,708 |
21,255 |
Consumer Goods |
19,729 |
20,056 |
20,257 |
20,454 |
72,241 |
55,821 |
Professional Hygiene |
10,184 |
10,123 |
9,422 |
9,617 |
34,393 |
24,392 |
Other |
21 |
-6 |
8 |
-31 |
-22 |
-2 |
Total |
37,092 |
37,078 |
36,352 |
36,629 |
131,320 |
101,466 |
ORGANIC SALES GROWTH BY BUSINESS AREA
( %) |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
5.8 |
8.0 |
10.6 |
4.5 |
7.2 |
5.5 |
Consumer Goods |
-0.4 |
5.7 |
14.8 |
18.4 |
17.6 |
0.2 |
Professional Hygiene |
5.7 |
11.7 |
22.6 |
20.7 |
25.4 |
5.8 |
Total |
2.4 |
7.7 |
15.9 |
16.0 |
17.3 |
2.6 |
SALES GROWTH, INCLUDING ORGANIC SALES GROWTH AND ACQUISITIONS BY BUSINESS AREA
( %) |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
5.8 |
8.0 |
10.6 |
6.4 |
9.6 |
6.6 |
Consumer Goods |
1.1 |
8.7 |
17.2 |
21.1 |
20.0 |
1.6 |
Professional Hygiene |
5.7 |
11.7 |
22.9 |
21.3 |
27.7 |
7.7 |
Total |
3.3 |
9.3 |
17.4 |
18.0 |
19.7 |
4.0 |
ADJUSTED EBITA BY BUSINESS AREA
SEKm |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
1,188 |
947 |
777 |
719 |
2,904 |
3,800 |
Consumer Goods |
2,395 |
2,417 |
2,400 |
2,293 |
6,354 |
5,767 |
Professional Hygiene |
1,887 |
1,582 |
1,288 |
1,405 |
3,843 |
2,673 |
Other |
-323 |
-329 |
-184 |
-305 |
-1,054 |
-789 |
Total |
5,147 |
4,617 |
4,281 |
4,112 |
12,047 |
11,451 |
ADJUSTED OPERATING PROFIT BY BUSINESS AREA
SEKm |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
979 |
737 |
560 |
499 |
2,058 |
3,082 |
Consumer Goods |
2,332 |
2,356 |
2,338 |
2,231 |
6,109 |
5,650 |
Professional Hygiene |
1,881 |
1,577 |
1,282 |
1,400 |
3,823 |
2,663 |
Other |
-322 |
-332 |
-182 |
-306 |
-1,054 |
-788 |
Total adjusted operating profit1 |
4,870 |
4,338 |
3,998 |
3,824 |
10,936 |
10,607 |
Financial items |
-644 |
-588 |
-625 |
-561 |
-1,320 |
-567 |
Profit before tax1 |
4,226 |
3,750 |
3,373 |
3,263 |
9,616 |
10,040 |
Income taxes |
-995 |
-941 |
-803 |
-815 |
-2,206 |
-2,474 |
Net profit for the period2 |
3,231 |
2,809 |
2,570 |
2,448 |
7,410 |
7,566 |
1Excluding items affecting comparability before tax amounting to: |
-1,967 |
-519 |
87 |
-305 |
-2,445 |
371 |
2Excluding items affecting comparability after tax amounting to: |
-1,668 |
-364 |
81 |
-226 |
-2,245 |
447 |
ADJUSTED EBITA MARGIN BY BUSINESS AREA
( %) |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
16.6 |
13.7 |
11.7 |
10.9 |
11.8 |
17.9 |
Consumer Goods |
12.1 |
12.1 |
11.8 |
11.2 |
8.8 |
10.3 |
Professional Hygiene |
18.5 |
15.6 |
13.7 |
14.6 |
11.2 |
11.0 |
Total |
13.9 |
12.5 |
11.8 |
11.2 |
9.2 |
11.3 |
ADJUSTED GROSS MARGIN BY BUSINESS AREA
( %) |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
42.0 |
39.0 |
37.8 |
36.3 |
37.4 |
42.7 |
Consumer Goods |
28.3 |
26.3 |
26.3 |
25.7 |
23.0 |
25.7 |
Professional Hygiene |
30.2 |
28.1 |
26.3 |
26.8 |
23.4 |
24.0 |
Total |
31.5 |
29.2 |
28.4 |
27.9 |
25.8 |
28.9 |
ADJUSTED RETURN ON CAPITAL EMPLOYED BY BUSINESS AREA
( %) |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
13.3 |
10.7 |
9.1 |
8.3 |
8.7 |
12.8 |
Consumer Goods |
17.2 |
17.6 |
18.2 |
16.7 |
12.8 |
14.2 |
Professional Hygiene |
28.0 |
22.7 |
18.6 |
19.3 |
14.0 |
11.7 |
Total |
17.2 |
15.8 |
15.2 |
13.9 |
10.9 |
12.4 |
OPERATING CASH FLOW BY BUSINESS AREA
SEKm |
2023:3 |
2023:2 |
2023:1 |
2022:4 |
2212 |
2112 |
Health & Medical |
1,676 |
323 |
270 |
818 |
2,396 |
3,834 |
Consumer Goods |
2,235 |
1,732 |
1,760 |
1,043 |
3,567 |
5,152 |
Professional Hygiene |
2,370 |
1,782 |
951 |
1,344 |
3,219 |
2,311 |
Other |
-227 |
-990 |
-111 |
-585 |
-1,503 |
-1,552 |
Total |
6,054 |
2,847 |
2,870 |
2,620 |
7,679 |
9,745 |
NET SALES BY CATEGORY
( %) |
2212 |
Health & Medical |
19 |
of which |
|
Incontinence Products Health Care |
11 |
Medical Solutions |
8 |
Consumer Goods |
55 |
of which |
|
Incontinence Products Retail |
7 |
Feminine Care |
8 |
Baby Care |
5 |
Consumer Tissue |
35 |
Professional Hygiene |
26 |
NET SALES PER REGION
( %) |
2212 |
Europe |
62 |
Latin America |
16 |
North America |
16 |
Asia |
2 |
Other |
4 |
For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55, [email protected]
Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89, [email protected]
The following files are available for download:
Essity reports Vinda as discontinued operations as of Q4 2023 and publishes updated comparable figures |
View original content:https://www.prnewswire.co.uk/news-releases/essity-reports-vinda-as-discontinued-operations-as-of-q4-2023-and-publishes-updated-comparable-figures-302019271.html
Fintech PR
Invitation to presentation of EQT AB’s Q1 Announcement 2024
![invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024](https://thefintechbuzz.com/wp-content/uploads/2024/04/51875-invitation-to-presentation-of-eqt-abs-q1-announcement-2024.png)
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
Fintech PR
Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs
![kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs](https://thefintechbuzz.com/wp-content/uploads/2024/04/51877-kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs.jpg)
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
Fintech PR
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
![biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update](https://thefintechbuzz.com/wp-content/uploads/2024/04/51873-biovaxys-technology-corp-provides-bi-weekly-mcto-status-update.jpg)
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
China remains stabilizing force for global economic growth
-
Latest News5 days ago
Kylian Mbappé and Accor Forge Alliance to Empower Younger Generations
-
Latest News3 days ago
Martello Re announces closing of $1.3 billion capital raise consisting of $935 million in equity and a $360 million upsize of the Company’s credit facility
-
Latest News4 days ago
BioCatch completes best first half in company history, grows ARR by 43% YoY
-
Latest News4 days ago
Market Dojo Celebrates Prestigious Inclusion in Ardent Partners 2024 Strategic Sourcing Technology Advisor
-
Latest News2 days ago
Driving Innovation Forward: CFI Welcomes Seven-Time Formula 1™ World Champion Lewis Hamilton as new Global Brand Ambassador
-
Latest News5 days ago
COP28 President calls on all stakeholders to bring spirit of solidarity that delivered UAE Consensus to drive implementation and sustainable socio-economic development
-
Latest News2 days ago
KEYSTONE BANK HOLDS CUSTOMER FORUM, REITERATES COMMITMENT TO EXCELLENT SERVICE DELIVERY